TAT1 is the tyrosine high-affinity transporter, which also mediates low-affinity or low-capacity uptake of tryptophan. TAT2 is the tryptophan high-affinity transporter. FK506 does not reduce the levels of TAT] and TAT2 transcripts, indicating that the inhibition of amino acid transport by the drug is posttranscriptional.
The immunosuppressive drugs FK506, cyclosporin A, and rapamycin block the activation and proliferation of quiescent T lymphocytes (39) . The effects of FK506 and cyclosporin A are mediated by a cis-trans-prolyl isomerase-drug complex that specifically interacts with and inhibits components of the signal transduction pathways leading to T-cell activation. The immunosuppressants also inhibit the growth of Saccharomyces cerevisiae by binding to the yeast homologs of the prolyl-isomerases (29) . Cyclosporin A binds cyclophilin; rapamycin and FK506 bind FKBP12. We previously demonstrated that for FK506, yeast cells contain a second, FKBP12-independent target which is involved in the uptake of amino acids (17, 18) . FK506 blocks the import of tryptophan, histidine, and leucine. Thus, strains auxotrophic for these three amino acids are sensitive to the drug, whereas prototrophy for one of these amino acids or an excess of tryptophan or histidine added exogenously to the growth medium is sufficient to overcome toxicity. The drug presumably interferes with the amino acid permeases mediating the uptake of these amino acids. Only 6 of the surmised ca. 20 amino acid transporters in S. cerevisiae have been cloned and sequenced: the general amino acid permease GAP1 (27) , the arginine high-affinity permease CAN1 (1, 24) , the lysine high-affinity permease LYP1 (42) , the proline high-affinity permease PUT4 (44) , the histidine highaffinity permease HIPM (43) , and the GAP1 homolog of unknown specificity YCC5 (35) . All appear to be derived from a common molecular ancestor, as they all encode integral membrane proteins that share 30 to 40% identity and contain 12 membrane-spanning regions. With the exception of GAP1, which possesses broad specificity for all L amino acids and most D isomers, the other transporters are highly specific for individual amino acids or small groups of structurally related amino acids. On the basis of biochemical and genetic data, there is evidence that the entry of most amino acids is mediated by a specific high-affinity system which can also import other similar amino acids with low affinity or low capacity (5, 26) . Thus, uptake of an amino acid can occur by at least three distinct routes: via the general amino acid permease GAP1, via a specific high-affinity permease, and via a lowaffinity permease. Little is known about the regulation of amino acid uptake other than for import mediated by GAP1 and PUT4. These transporters belong to the uptake systems that are subject to nitrogen source regulation and are thus repressed during growth on a good nitrogen source such as ammonium (6, 13, 26, 28, 31, 47) . Inhibition by ammonium ions involves at least two distinct control mechanisms: repression of transcription of the transporter genes mediated by the URE2 gene product (31, 47) and posttranscriptional inactivation of the transporters by the action of the nitrogen permease inactivators NPI1 and NPI2 (13) . In the absence of ammonium ions, permease inactivation is counteracted by the putative Ser-Thr kinase NPR1 (14, 45, 46) . Regulation of the other, "constitutive" amino acid permeases at the transcriptional level has not been demonstrated; it has been described only as feedback inhibition and transinhibition at the protein level (5) . Feedback inhibition explains the observation that high intracellular levels of a transported amino acid prevent the further uptake of this amino acid, perhaps by occupying the transporter. In the case of transinhibition, the inhibiting molecules are not transported by the inhibited uptake system and show little or no structural similarity to the physiological substrate.
Here we describe the characterization of two new genes, TA Tl and TA T2, overexpression of which confers resistance to FK506 (17) . We find that the TAT1 and TAT2 proteins are novel members of the yeast amino acid permease family and that they mediate tyrosine and tryptophan high-affinity uptake, respectively. TAT1 and TAT2 were formerly called TAPI and TAP2 (16, 17) ; the names were changed to avoid conflict with a previous use of the TAP designation for a yeast gene (2) .
MATERUILS AND METHODS
Strains, media, and plasmids. S. cerevisiae strains used in this study are listed in Table 1 . Media were as described previously (40) . Proline medium was made by using Bacto Yeast Nitrogen Base (Difco) without amino acids and ammonium sulfate (according to the Difco manual), adding glucose to a final concentration of 3% and proline to a final concentration of 1 mg/ml, and supplementing the medium with 1A ). Plasmid pTAT2 is YCplac33 carrying a 4.2-kb genomic DNA insert containing the TAT2 gene (see Fig. 1A ). Plasmids pAS5 and pAS6 were constructed by cloning the 3.0-kb HindIII fragment of TATl derived from pTAT1 and the 3.7-kb EcoRI fragment of TAT2 derived from pTAT2 into the high-copynumber vector YEplacl81 (Ampr 2,um LEU2) (10). pGCN4 is plasmid p238 (a gift from A. Hinnebusch) containing a GCN4 allele with the four upstream open reading frames inactivated by point mutations in the ATG codons. Genetic techniques. Yeast mating, sporulation, and tetrad analysis were performed as described previously (15) . Yeast transformation was performed by the lithium acetate procedure (23) . Escherichia coli MH1 (araD lac galE galK hsr rpsL) was used for propagation and isolation of plasmid DNA as described previously (37) .
DNA manipulations. Restriction enzyme digests and ligations were done by standard methods (37) . All enzymes and buffers were obtained commercially (Boehringer GmbH). DNA probes for Southern analysis were labeled by using the random-prime labeling kit (Amersham International) as recommended by the manufacturer. Total yeast genomic DNA was isolated as described previously (36) , fractionated by gel electrophoresis on an agarose gel in Tris-borate-EDTA, and transferred to nylon membranes. Prehybridization and hybridization were performed as recommended by the manufacturer (Amersham International). DNA was sequenced by the dideoxy-chain termination method (38) with the T7 sequencing system (Pharmacia). Overlapping deletions of the TAT2 gene were obtained from plasmids pTAT2 and pAS2 (see below) by the exonuclease III method with the Erase-a-Base system (Promega). Custom-made oligonucleotides were used as primers for sequencing regions not accessible with deletions or subclones.
RNA manipulations. DNA probes for Northern (RNA) analysis were either labeled by using the direct nucleic acidlabeling kit (Amersham International) or the random-primed DNA-labeling kit (U.S. Biochemicals). Total RNA from exponentially growing cells was isolated as described previously (9) , fractionated in morpholinepropanesulfonic acid (MOPS)-formaldehyde, and transferred to nylon membranes. Prehybridization and hybridization were performed under conditions recommended by the manufacturer (Amersham International) for enhanced chemiluminescence (ECL) detection or by the method of Sambrook et al. (37) for radioactive detection.
Disruption of the TAT) and TAT2 genes. The 3.0-kb EcoRI fragment of TAT1 and the 3.7-kb EcoRI fragment of TAT2 were excised from the original TAT1 and TAT2 clones, respectively, and subcloned into the EcoRI site of YCplac33, from which the BamHI and Sall sites had previously been removed (pAS1 and pAS2). This was followed by the insertion of the BamHI fragment of the URA3 gene from pUC1318 (obtained from M. Egerton and H. Riezman, Biozentrum, University of Basel) into the unique BamHI site of TAT] and TAT2 (see Fig.  1B ). The resulting plasmids were linearized with EcoRI and BglII, and the disruption fragments were transformed directly into the prototrophic strain MH339, selecting for URA +. Disruptions were verified by Southern analysis. Diploid strains that showed the expected hybridization pattern were designated AS1 (tatl::URA3/TATi) and AS2 (tat2::URA3ITAT2).
Disruption of GCN4. GCN4 was disrupted by transforming the 3.7-kb BstEII-MluI fragment of plasmid pM214 (a gift from A. Hinnebusch) into JK9-3da/a. The disruption was verified by Southern analysis. A homozygous gcn4 diploid (TK201) was constructed by mating two haploid gcn4::URA3 segregants from the original, diploid, heterozygous disruption strain.
Amino acid import studies. Yeast strains grown to logarithmic phase in YPD were harvested and assayed for the uptake of 3H-labeled amino acids as described previously (16, 17 (Fig. 2 ).
Northern analysis with the EcoRI fragments of TAT] and TAT2 as probes revealed mRNAs of the expected size. For both genes, a single mRNA of approximately 2 kb was overexpressed in strains containing the relevant TAT gene on a multicopy vector and was missing in strains disrupted at the corresponding TAT locus (data not shown).
The TAT1 and TAT2 proteins deduced from the nucleotide sequences show 39.7% identity, and 51 and 52% of the amino acids, respectively, are hydrophobic residues. The hydropathy profiles of TAT1 and TAT2 suggest that there are 12 membrane-spanning regions. TAT1 and TAT2 thus show characteristics typical of transmembrane transport proteins, although they do not contain an obvious cleavable N-terminal signal sequence. Searches of databases by using the FASTA program (8) revealed that the polypeptides deduced from the nucleotide sequences have 30 to 50% identity to the known yeast amino acid permeases GAP1, CAN1, LYPl, HIP1, PUT4, and YCC5 (a GAP1 homolog found by sequencing the yeast chromosome III) (35) . Alignments obtained with the BEST-FIT and PILEUP programs (8) revealed 49 identical amino acids, including 8 prolines and most of the tryptophan and glutamate residues. Almost 200 amino acids are conservatively replaced. All seven transport proteins exhibit 12 transmembrane domains, and, except for the N-and C-terminal regions, the Kyte-Doolittle patterns are practically superimposable. An alignment of the amino acid sequences of TAT1, TAT2, GAP1, CAN1, LYPl, PUT4, HIP1, and YCC5 is displayed in Fig. 3 .
The sequences of the TAT] and TAT2 genes and the homology in the deduced amino acid sequence and protein structure to the other cloned amino acid permeases in S. cerevisiae strongly suggested that both TAT1 and TAT2 are amino acid permeases.
Analysis of the upstream region of the TAT2 gene reveals at least three sequence motifs, at positions -80 (TGACTG), -85 (TGACTT), and -142 (TCACTC), that resemble the consensus sequence required for GCN4 binding (TGACTC). GCN4 is a transcription factor that is responsible for the activation of a set of >30 genes required for amino acid or purine biosynthesis in response to amino acid or purine starvation (3, 19-22, 25, 35, 42 
1TAACATCATCCTCATCACACAATTCAAACTCATCGCATCACGATGATGACAACCAACACGCAGCGATGTGTTGATTCTTTCA 195 TAT1  TAT2  CAN1  GAP1   HIPM   LYP1   PUT4   YCCS   TAT1  TAT2  CAN1  GAP1  HIP1  LYP1  PUT4   YCC5   TAT1  TAT2   CANM   GAP1  HIP1   LYPi   PUT4   YCCS   TAT1  TAT2   CANM  GAP1  HIPM  LYP1  PUT4   YCC5   TAT1  TAT2  CAN1  GAP1  HIP1  LYP1  PUT4  YCC5   TAT1  TAT2  CAN1  GAP1  HIP1  LYP1  PUT4  YCC5   TAT1   TAT2   CAN1  GAP1  HIP1 (1, 42) . Thus, the transcription of at least some constitutive amino acid permease genes might be under general control. In a model in which TAT2 transcription is regulated by GCN4, not only overexpression of TAT2 but also overexpression of GCN4 should confer resistance to FK506 by increasing TAT2 levels. However, cells constitutively expressing GCN4 are still FK506 sensitive (Fig. 4) . Furthermore, disruption of GCN4 does not result in FK506 hypersensitivity but, surprisingly, confers resistance to the immunosuppressant (Fig. 4) . Finally, we found by Northern analysis that a GCN4 disruption does not alter the expression of TAT2 (data not shown). Thus, the TAT2 gene is not under general control but is constitutively expressed. (Fig. 1B) . The successful disruption of the TAT2 locus in the diploid amino acid prototroph MH339 was verified by Southern analysis (data not shown). The resulting strain heterozygous for the TAT2 disruption, AS2, was sporulated and dissected on YPD. All tetrads yielded four viable spores with the URA3 disruption marker segregating 2:2. It was concluded that TAT2 is not essential for the growth of prototrophic yeast cells. The haploid strain AS2-lc (tat2::URA3) was crossed to the auxotrophic strain JK9-3da (trpl his4 leu2 ura3). Dissection of the resulting diploid strain AS4 (tat2::URA3ITAT2 trplITRPl his4/ HIS4 keu2/LEU2 ura3lura3) revealed that the disruption of the TAT2 gene conferred a growth defect when combined with trpl. Of 51 dissected tetrads, only 18 yielded four visible colonies, whereas three spores were recovered from 18 tetrads and two spores were recovered from the remaining 15 tetrads after 2 days of incubation at 30°C (Fig. 5A) . None of these segregants were tat2::URA3 trpl, whereas almost all of the nongrowing spores were inferred to have this genotype. Interestingly, the tat2::URA3 trpl segregants were not dead but showed a slow-growth phenotype, since they were visible as colonies after 4 days of incubation (Fig. 5A ). This suggested that TAT2 encodes a tryptophan high-affinity transporter and also that a second, low-affinity or low-capacity transporter for tryptophan exists. To test this, we dissected strain AS6 (tat2::URA3/TAT2 trpl/TRPl) on medium containing a 50-fold excess of tryptophan. Indeed, after 3 days of incubation, all four spores were growing normally, confirming the presence of a second tryptophan transporter (Fig. 5A) . Furthermore, dissection of strain AS6 on medium containing proline as the sole nitrogen source, such that the general amino acid permease GAP1 is derepressed, also yielded four almost equally growing spore colonies (Fig. 5A ). This suggested that tryptophan import can also occur via GAP1 and that the activation of this transport system is sufficient to overcome the slow-growth phenotype of tat2::URA3 trpl cells.
L T S S S S H N S N S S H H
To obtain biochemical evidence that TAT2 is the tryptophan high-affinity permease, we performed amino acid import studies measuring the uptake of radiolabeled tryptophan, tyrosine, and histidine into strains AS2-lc (TAT1 tat2::URA3) and MH338-2a (TAT1 TAT2). Figure 6 shows that the import of Spores of strain AS4 (JK9-3da/a tat2::URA3/TAT2 trpl/TRPl his4/HIS4 leu2/LEU2) were germinated on YPD for 2 or 4 days. tat2::URA3 trpl spores show a slow-growth phenotype. Spores of strain AS6 (JK9-3da/a. tat2:: URA3ITAT2 trplITRPl HIS4IHIS4 LEU2ILEU2) were germinated on YPD medium containing a 50-fold excess of tryptophan (1 mg/ml of YPD) and on medium containing proline as the sole nitrogen source (see Materials and Methods). Under these conditions, the slow-growth phenotype of tat2::URA3 trpl cells is suppressed. (B) Growth of tatl:: URA3 tyrl segregants. Spores of strain AS10 (a/ct tatl::URA3/TATl tyr/TYRl trplITRPl his4IHIS4 ade2/ADE2 lys2/LYS2 ura3/ura3) were germinated on YPD. tatl::URA3 tyrl cells are inviable. (C) Growth of tatl::URA3 tat2::URA3 trpl segregants. Spores of strain AS12 (JK9-3da/la tatl::URA3/tat1::URA3 tat2::URA3/TAT2 trpl/TRPJ HIS4/HIS4 LEU2/LEU2) were germinated on YPD for 4 days. tatl::URA3 tat2:: URA3 trpl cells are inviable. In all cases, the four spores of a tetrad are aligned vertically.
tryptophan is severely decreased when TAT2 is disrupted. Import of the other amino acids, tyrosine and histidine, was not affected upon disruption of TAT2, indicating that the observed effect is specific for tryptophan. Thus, according to the above genetic and biochemical evidence, TAT2 is a tryptophan high-affinity transporter.
TAT1 is a tyrosine transporter. The TAT1 gene was disrupted by insertion of the URA3 marker into the unique BamHI site within the TAT1 gene (see Materials and Methods) (Fig. 1B) . The disrupted gene was excised and was transformed into the diploid strain MH339. Disruption of the TAT1 gene was confirmed by Southern analysis (data not shown). Strain AS1 (tat1::URA3/TATi) was sporulated and dissected on YPD. All tetrads yielded four viable spores with the URA3 marker segregating 2:2. The haploid strain AS1-3c YPD. Dissection of all strains except for strain AS10 (tatl::URA3/TATl tyri/TYRJ trpl/TRPJ his3/HIS3 ade2/ADE2 lys!LYS2 ura3!ura3) yielded four viable spores. Of the 30 dissected tetrads of AS10, 24 yielded only three viable spores, 5 yielded four viable spores, and 1 yielded only two viable spores (Fig. 5B) . None of the viable spores were tatl::URA3 tyrl, whereas almost all inviable cells were inferred to have this genotype. Thus, because absence of import and biosynthesis at the same time would prevent cell growth, TAT] most probably encodes a permease involved in tyrosine high-affinity uptake. To test this directly, amino acid import studies were performed to measure the uptake of radiolabeled tyrosine, tryptophan, and histidine into strains AS1-3c (tatl::URA3 TAT2) and MH338-2a (TAT1 TAT2). As can be seen in Fig. 6 , tyrosine uptake is abolished in tatl::URA3 cells compared with wildtype strains, confirming that TAT1 is indeed a tyrosine highaffinity transporter. Import of histidine, which served as control, was not affected upon disruption of TAT]. However, uptake of tryptophan was slightly decreased in cells lacking TAT1, suggesting that TAT1 might also be involved in tryptophan uptake and might be the second transporter responsible for the viability of tat2::URA3 trpl cells (see above).
TAT1 is also a tryptophan low-affinity or low-capacity transporter. A strain disrupted for both TAT] and TAT2, AS11-la, was crossed to the trpl strain MH338-7b. Dissection of the diploid strain, AS13, revealed that when all three markers (tatl::URA3, tat2::URA3, and trpl) segregated together, the spores no longer exhibited a slow-growth phenotype but were inviable (Fig. SC) . Furthermore, we examined whether overexpression of TAT1 could restore normal cell growth to tat2::URA3 trpl cells. High-copy-number plasmids pAS5 and pAS6 (YEplacl81 based) carrying the entire TAT1 and TAT2 genes, respectively, were transformed into strain AS4 (tat2::URA3/TAT2 trpl/TRPl his4/HIS4 leu2/leu2). Plasmid YEplacl81 without insert was transformed as a control. Transformants were sporulated and dissected on YPD. Overproduction of either TAT1 or TAT2 completely complemented the slow-growth phenotype of tat2::URA3 trpl spores. Plasmid YEplacl81 alone did not suppress the slow-growth phenotype. Thus, TAT1 is the second tryptophan transporter in addition to being a tyrosine high-affinity transporter.
We also examined whether a high dosage of TAT2 complements a TAT] disruption. The high-copy-number plasmids YEplacl81 (no insert), pAS5 (TAT1), and pAS6 (TAT2) were transformed into strain AS20 (tat1::URA3/TATl tyrl/TYRI leu2/leu2). Transformants were dissected on YPD, and only the TA Ti plasmid was able to restore normal cell growth of tatl::URA3 tyr] cells. The high-copy-number TAT2 plasmid and the control failed to suppress the TAT] disruption. Thus, in agreement with our previous results, TAT2 does not transport tyrosine.
Import studies with the doubly disrupted strain AS11-la (tatl::URA3 tat2::URA3) were performed (Fig. 6 ). Tryptophan uptake was most severely affected in the doubly disrupted strain, presumably as a result of an additive effect of the lack of import due to absence of both tryptophan transporters. The finding that in the TAT doubly disrupted strain tryptophan import is almost completely abolished is consistent with our previous finding that the double disruption is not compatible with a tipl genetic background.
Disruption of TAT] but not of TAT2 confers resistance to 5F1. 5-Fluorotryptophan (SFT) is a toxic analog of tryptophan and acts most probably by inhibiting anthranilate synthase, which is required for tryptophan biosynthesis and is controlled by tryptophan via negative feedback (4, 33) . SFT seems to mimic tryptophan in turning off the enzyme's activity. In addition, 5FT is incorporated into proteins, causing an accumulation of defective proteins (33) . SFT is thought to enter the cells via amino acid transporters, most probably by the tryptophan high-affinity transporter TAT2. We therefore tested whether disruption of TAT2 would confer resistance to SFT. Strains disrupted in TAT], TAT2, or both transporter genes were thus incubated on SD-Trp plates containing 0.5 mM SFT (Fig. 7) . Surprisingly, cells disrupted in the TAT2 locus and cells disrupted in both transporter genes were resistant to SFT but cells disrupted in TAT2 alone were sensitive. This suggests that 5FT enters the cells not via the tryptophan high-affinity transporter but via the tyrosine high-affinity permease.
Disruption of TAT] confers resistance to FK506. Overexpression of TAT] and TAT2 confers FK506 resistance on normally FK506-sensitive auxotrophic diploids (Fig. 8) . (17) . We therefore tested the effect of a TAT] disruption on growth inhibition by FK506. Surprisingly, we found that the auxotrophic strain AS14 disrupted for TAT] (tat]::URA3/tat1::URA3) is resistant to FK506, in contrast to the wild-type auxotrophic strain JK9-3da/a (TATI/TAT]) (Fig. 8) 
DISCUSSION
The immunosuppressive drug FK506 impairs the growth of the yeast S. cerevisiae by impeding the uptake of the amino acids tryptophan, histidine, and leucine and thus starving cells for these amino acids (17) . Toxicity of the drug can be overcome by prototrophy for either one of these amino acids or by an excess of amino acids added exogenously to the growth medium. The inhibition of amino acid import by FK506 is not attributable to the binding of the drug to its known binding protein, the cis-trans-prolyl isomerase FKBP12, since amino acid transport is still FK506 sensitive in strains lacking this rotamase (17, 18) . Thus, a second target, which is involved either directly or indirectly in the amino acid import machinery, must exist. Two novel genes, TA Ti and TA T2 (formerly called TAP] and TAP2), were isolated as genes conferring resistance to FK506 when present at increased levels. Here, we show that TA Ti and TA T2 encode novel members of the yeast amino acid permease family. TAT1 is a 619-amino-acid protein and is the tyrosine high-affinity permease that also mediates tryptophan uptake with low affinity or low capacity. TAT2 is a 593-amino-acid protein and mediates the high-affinity uptake of tryptophan. The evidence for these conclusions is as follows. First, disruption of TAT1 is lethal only in combination with auxotrophy for tyrosine; cells that are unable to synthesize or import tyrosine are starved for this amino acid and therefore unable to grow. Disruption of TAT2 results in only a slowgrowth phenotype when combined with tryptophan auxotrophy. Thus, high-affinity uptake of tryptophan is mediated by TAT2 and a second, low-affinity or low-capacity transporter, responsible for the viability of tat2::URA3 trpl cells, must exist. Second, providing an excess of tryptophan to the growth medium restores normal cell growth of tat2::URA3 trpl cells. Third, the rate of import of labeled tyrosine and tryptophan is strongly decreased in cells lacking TAT1 and TAT2, respectively, compared with wild-type cells or with the uptake of other amino acids such as histidine. Fourth, 30 to 40% identity in the deduced amino acid sequence and the striking homology in the protein structure to the known yeast amino acid transporters GAP1, CAN1, LYPl, PUT4, HIP1, and YCC5 strongly suggest that TAT1 and TAT2 are amino acid permeases. Fifth, the lethality of a tatl::URA3 tat2::URA3 double disruption in combination with tryptophan auxotrophy and the finding that uptake of tryptophan is affected more severely in the doubly disrupted strain than in a strain lacking only TAT2 shows that TAT1 is involved in the low-affinity or low-capacity uptake of tryptophan. Furthermore, overexpression of TAT] is sufficient to overcome the slow-growth phenotype of tat2:: URA3 trpl cells and restores normal cell growth.
The discovery of two tryptophan transporters, one mediating high-affinity uptake and the other mediating low-affinity or low-capacity uptake, conflicts with several reports stating that a specific transporter for tryptophan does not exist and that tryptophan uptake is mediated exclusively by the general amino acid permease GAP1 (11, 30, 48) . Our findings that cells which lack TAT2 and are auxotrophic for tryptophan grow normally on proline medium, on which the general amino acid permease is active, support the previous reports that tryptophan is also a substrate for GAP1. However, since gapl trp3 double mutants are viable on YPD medium (32), tryptophan import must indeed occur by transport systems other than GAP1. Other groups have observed that a specific transport system for asparagine might also transport tryptophan, since asparagine uptake was found to be competitively inhibited by a 10-fold excess of tryptophan (12) . The fact that tatl::URA3 tat2::URA3 trpl cells grow normally on SD complete medium containing a 50-fold excess of Trp (data not shown), although they are not viable on YPD and their uptake of tryptophan is almost completely abolished, argues that there might be a third transporter importing tryptophan with very low affinity. This transporter might be the asparagine transport system. Very little is known regarding the uptake of tyrosine. GAP1 imports tyrosine (30) . Furthermore, the low-affinity permease of histidine is competitively inhibited by tyrosine, suggesting that tyrosine is also a substrate for this transporter (7) . It is unlikely that TAT1 is the histidine low-affinity permease, because the histidine low-affinity permease has been shown not to mediate transport of the other aromatic amino acids tryptophan and phenylalanine and because disruption of TAT] has no effect on histidine import.
The mechanism of action of FK506 on amino acid transporters is not yet known. However, we have shown that the immunosuppressant does not inhibit the transcription of the transporter genes TAT] and TAT2. Northern analysis revealed that the TAT] and TAT2 mRNAs are slightly more abundant in cells treated with FK506. This suggests that the drug inhibits a posttranscriptional step required for the function of the amino acid permeases. FK506 might prevent the correct folding of amino acid transporters in the secretory pathway by binding to an unknown FKBP, whose isomerase activity is required for permease maturation. Alternatively, the drug might act on a component involved in the control of amino acid permeases. A third model suggests that FK506 affects the composition of the plasma membrane or the proton ATPases which generate the H+ gradient providing the energy for amino acid import. All of these possibilities are discussed in greater detail in our previous paper (17) , and none can be excluded yet.
